Evidence map›Paper›PMID 23863802›Full record

ReviewJournal of human hypertension2014

CYP3A5 polymorphism, amlodipine and hypertension.

Y-P Zhang, X-C Zuo, Z-J Huang, J-J Cai, J Wen, D D Duan, H Yuan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of human hypertension, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cinnamon modulates the pharmacodynamic & pharmacokinetic of amlodipine in hypertensive rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  12. Article
  13. Article
  14. Adverse Drug Reactions of Antihypertensives andFrontiers in pharmacology · 2022
    Article
  15. Article
  16. Article
  17. Association ofPharmacogenomics and personalized medicine · 2021
    Article
  18. Precision cardiovascular medicine in China.Journal of geriatric cardiology : JGC · 2020
    Article
  19. Genetics and ESKD Disparities in African Americans.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Y-P Zhang1] Department of Cardiology, the Third Xiang-Ya Hospital, Central South University, Changsha, People's Republic of China [2] Center of Clinical Pharmacology, the Third Xiang-Ya Hospital, Central South University, Changsha, China.
X-C ZuoCenter of Clinical Pharmacology, the Third Xiang-Ya Hospital, Central South University, Changsha, China.
Z-J HuangCenter of Clinical Pharmacology, the Third Xiang-Ya Hospital, Central South University, Changsha, China.
J-J Cai1] Department of Cardiology, the Third Xiang-Ya Hospital, Central South University, Changsha, People's Republic of China [2] Center of Clinical Pharmacology, the Third Xiang-Ya Hospital, Central South University, Changsha, China.
J Wen1] Department of Cardiology, the Third Xiang-Ya Hospital, Central South University, Changsha, People's Republic of China [2] Center of Clinical Pharmacology, the Third Xiang-Ya Hospital, Central South University, Changsha, China.
D D DuanLaboratory of Cardiovascular Phenomics, the Department of Pharmacology, University of Nevada School of Medicine, Reno, NV, USA.
H Yuan1] Department of Cardiology, the Third Xiang-Ya Hospital, Central South University, Changsha, People's Republic of China [2] Center of Clinical Pharmacology, the Third Xiang-Ya Hospital, Central South University, Changsha, China.
Central South University · CNUniversity of Nevada, Reno · US

Funding

The CLC-3 chloride channels in the heartR01HL113598 · NHLBI · UNIVERSITY OF NEVADA RENO · PI DUAN, DAYUE DARREL · 2013 to 2016
$1.4M
NHLBI NIH HHS R01 HL113598
6 · The paper itself

Abstract

As a major cardiovascular risk factor for stroke, coronary artery disease, heart failure and end-stage renal disease, hypertension affects approximately one billion people and causes large economic burden worldwide. Cytochrome P450 3A5 (CYP3A5), belonging to the CYP3A subfamily, has been implicated in the regulation of blood pressure and may serve as a potential risk factor for the development of hypertension. Increased CYP3A5 activity could cause sodium and water retention by affecting the metabolism of cortisol in the kidneys. Furthermore, polymorphic CYP3A5 genotypes have been shown to cause differences in blood pressure response to antihypertensive drugs. Several studies have investigated the role of CYP3A5 in blood pressure response to amlodipine. However, recent data on the role of CYP3A5 in hypertension development and treatment are inconsistent. This review summarizes what is known regarding the relationship of CYP3A5 with hypertension, discusses the limitations in present studies, highlights the gaps and directs research to this field.

Indexed as

Polymorphism, GeneticAmlodipineAntihypertensive AgentsCytochrome P-450 CYP3AGenotypeHumansHypertensionAmlodipineAntihypertensive AgentsCYP3A5 protein, humanCytochrome P-450 CYP3A

Identifiers

PMID23863802
OpenAlexW2010480872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.